A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cytarabine/daunorubicin (Primary) ; Ruxolitinib (Primary) ; Stem cell therapies
Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
Focus Adverse reactions; Therapeutic Use

11 Apr 2024 Status changed from suspended to recruiting.
09 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
09 Feb 2024 Status changed from recruiting to suspended for internal reporting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com